Skip to main content
OpenTrials

Clinical trial condition

Fallopian Tube Diseases

Explore clinical trials studying Fallopian Tube Diseases. Study availability and eligibility vary by location and protocol.

606 public trials 90 recruiting studies
Refine in advanced search Browse all conditions

Fallopian Tube Diseases trial results

Recruiting

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT06890338

Conditions
Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +22 more
Locations
  • University of Alabama at Birmingham (UAB) Hospital /ID# 274793 Birmingham, Alabama, United States
  • Usa Mitchell Cancer Institute /ID# 276022 Mobile, Alabama, United States
  • University of California Los Angeles Medical Center /ID# 274566 Los Angeles, California, United States
  • Scripps Md Anderson - Prebys Cancer Center /ID# 276891 San Diego, California, United States
View all 70 locations
View Trial Details
Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377

Conditions
Adnexal Diseases, Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, +36 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
View all 482 locations
View Trial Details
Recruiting

An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

NCT07604766

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +15 more
Locations
  • Chongqing University Cancer Hospital - Chongqing Cancer Hospital Chongqing, China
  • Fudan University Shanghai Cancer Hospital Shanghai, China
  • Obstetrics & Gynecology Hospital of Fudan University Shanghai, China
  • Tianjin Medical University Cancer Institute & Hospital Tianjin, China
View all 17 locations
View Trial Details
Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804

Conditions
Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, +23 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • HonorHealth Phoenix, Arizona, United States
  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center Burbank, California, United States
  • City of Hope, Duarte Duarte, California, United States
View all 267 locations
View Trial Details
Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • University of Alabama at Birmingham ( Site 0006) Birmingham, Alabama, United States
  • Alaska Women's Cancer Care ( Site 0096) Anchorage, Alaska, United States
  • UCSF Medical Center at Mission Bay ( Site 0013) San Francisco, California, United States
  • John Muir Health Cancer Center ( Site 0016) Walnut Creek, California, United States
View all 196 locations
View Trial Details
Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471

Conditions
Adnexal Diseases, DNA Virus Infections, Endocrine Gland Neoplasms, +26 more
Locations
  • The University of South Alabama, Mitchell Cancer Institute Mobile, Alabama, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • City of Hope Duarte, California, United States
  • UC San Diego Health - Moores Cancer Center La Jolla, California, United States
View all 33 locations
View Trial Details
Recruiting

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

NCT04590326

Conditions
Adnexal Diseases, Disease Attributes, Endocrine Gland Neoplasms, +25 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • The City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
  • Chao Family Comprehensive Cancer Center Orange, California, United States
  • H. Lee Moffitt Cancer Center Tampa, Florida, United States
View all 28 locations
View Trial Details
Recruiting

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

NCT06792552

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Solid Tumors, +35 more
Locations
  • Sarah Cannon Research Institute (SCRI) - Lake Nona Orlando, Florida, United States
  • Emory Winship Cancer Institute Atlanta, Georgia, United States
  • University Medical Center of New Orleans LSU-LCMC Health Cancer Center New Orleans, Louisiana, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 17 locations
View Trial Details

Related conditions